In this multiple-center phase II study, the aim is to evaluate the clinical outcome of reduced intensity conditioning regimen with fludarabine (150mg/m2), busulfan (6.4mg/kg) and melphalan (100mg/m2) in patients with myeloid malignancies including AML, MDS and CMML \>=55 years.
Age 55-65
patients with HLA-matched sibling donors, 9-10/10 matched unrelated donors or haplo-identical donors.
patients with AML in remission, or MDS in any stage, or CMML in any stage
inform consent provided
patients with abnormal liver (>3N), renal (1.5N) or cardiac function
patients with active infection